KR20200033348A - C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 - Google Patents

C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 Download PDF

Info

Publication number
KR20200033348A
KR20200033348A KR1020207007296A KR20207007296A KR20200033348A KR 20200033348 A KR20200033348 A KR 20200033348A KR 1020207007296 A KR1020207007296 A KR 1020207007296A KR 20207007296 A KR20207007296 A KR 20207007296A KR 20200033348 A KR20200033348 A KR 20200033348A
Authority
KR
South Korea
Prior art keywords
ser
val
leu
antibody
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207007296A
Other languages
English (en)
Korean (ko)
Inventor
겐지 시노미야
게이스케 고탄다
준이치 니시무라
에리카 윈터
조이 씨 쉬
Original Assignee
추가이 세이야쿠 가부시키가이샤
오사카 유니버시티
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤, 오사카 유니버시티, 에프. 호프만-라 로슈 아게 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20200033348A publication Critical patent/KR20200033348A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207007296A 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 Ceased KR20200033348A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862713211P 2018-08-01 2018-08-01
US62/713,211 2018-08-01
US201862764952P 2018-08-17 2018-08-17
US62/764,952 2018-08-17
US201862760204P 2018-11-13 2018-11-13
US62/760,204 2018-11-13
PCT/JP2019/030283 WO2020027279A1 (en) 2018-08-01 2019-08-01 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197036896A Division KR20200033225A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217009235A Division KR20210037743A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법

Publications (1)

Publication Number Publication Date
KR20200033348A true KR20200033348A (ko) 2020-03-27

Family

ID=67660420

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020207007296A Ceased KR20200033348A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
KR1020217009235A Ceased KR20210037743A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
KR1020217009233A Ceased KR20210038697A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
KR1020247023205A Pending KR20240115904A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
KR1020197036896A Ceased KR20200033225A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020217009235A Ceased KR20210037743A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
KR1020217009233A Ceased KR20210038697A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
KR1020247023205A Pending KR20240115904A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
KR1020197036896A Ceased KR20200033225A (ko) 2018-08-01 2019-08-01 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법

Country Status (23)

Country Link
US (1) US20210301004A1 (OSRAM)
EP (2) EP3829628B1 (OSRAM)
JP (4) JP6672516B2 (OSRAM)
KR (5) KR20200033348A (OSRAM)
CN (1) CN112512563A (OSRAM)
AU (2) AU2019315213B2 (OSRAM)
BR (1) BR112021001655A2 (OSRAM)
CA (1) CA3107618A1 (OSRAM)
CR (1) CR20210103A (OSRAM)
DE (1) DE112019003835T5 (OSRAM)
ES (1) ES2980137T3 (OSRAM)
HR (1) HRP20240823T1 (OSRAM)
HU (1) HUE067057T2 (OSRAM)
IL (1) IL280475B1 (OSRAM)
MX (2) MX2021000516A (OSRAM)
MY (1) MY210523A (OSRAM)
PH (1) PH12021550226A1 (OSRAM)
PL (1) PL3829628T3 (OSRAM)
RS (1) RS65630B1 (OSRAM)
SG (1) SG10202002898RA (OSRAM)
SM (1) SMT202400271T1 (OSRAM)
TW (2) TWI704157B (OSRAM)
WO (1) WO2020027279A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029697A1 (en) 1994-05-02 1995-11-09 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
WO2002030985A2 (en) 2000-10-10 2002-04-18 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
WO2004007553A1 (en) 2002-07-11 2004-01-22 Universita' Degli Studi Di Trieste Antibodies anti-c5 component of the complement system and their use
WO2005074607A2 (en) 2004-02-03 2005-08-18 Alexion Pharmaceuticals, Inc. Method of treating hemolytic disease
WO2007106585A1 (en) 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2008069889A2 (en) 2006-11-08 2008-06-12 Alexion Pharmaceuticals, Inc. Methods of treating hemolytic anemia
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
WO2010054403A1 (en) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2011122011A2 (en) 2010-03-30 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Antibodies with modified affinity to fcrn that promote antigen clearance

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CA2899589C (en) * 2013-01-31 2022-02-22 Seoul National University R & Db Foundation C5 antibody and method for preventing and treating complement-related diseases
TWI617580B (zh) * 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
EP4269440A3 (en) * 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US20190023775A1 (en) * 2016-01-11 2019-01-24 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
MA53248A (fr) 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co Anticorps anti-c5 à commutation ph améliorée
BR112020008182A2 (pt) * 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
KR20200095485A (ko) * 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355245B1 (en) 1994-05-02 2002-03-12 Alexion Pharmaceuticals, Inc. C5-specific antibodies for the treatment of inflammatory diseases
WO1995029697A1 (en) 1994-05-02 1995-11-09 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
WO2002030985A2 (en) 2000-10-10 2002-04-18 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
WO2004007553A1 (en) 2002-07-11 2004-01-22 Universita' Degli Studi Di Trieste Antibodies anti-c5 component of the complement system and their use
WO2005074607A2 (en) 2004-02-03 2005-08-18 Alexion Pharmaceuticals, Inc. Method of treating hemolytic disease
WO2007106585A1 (en) 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2008069889A2 (en) 2006-11-08 2008-06-12 Alexion Pharmaceuticals, Inc. Methods of treating hemolytic anemia
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
WO2010054403A1 (en) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2011122011A2 (en) 2010-03-30 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Antibodies with modified affinity to fcrn that promote antigen clearance

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Dall'Acqua et al., J. Immunol. 169(9):5171-5180 (2002)
Datta-Mannan et al., J Biol. Chem. 282(3):1709-1717 (2007)
Dmytrijuk et al., The Oncologist 13(9):993-1000 (2008)
Holers et al., Immunol. Rev. 223:300-316 (2008)
Yeung et al., J Immunol. 182(12): 7663-7671 (2009)

Also Published As

Publication number Publication date
US20210301004A1 (en) 2021-09-30
EP3829628A1 (en) 2021-06-09
SMT202400271T1 (it) 2024-07-09
AU2019315213A1 (en) 2021-03-25
JP2020079331A (ja) 2020-05-28
CA3107618A1 (en) 2020-02-06
WO2020027279A1 (en) 2020-02-06
CR20210103A (es) 2021-03-22
JP2020073608A (ja) 2020-05-14
SG10202002898RA (en) 2020-05-28
ES2980137T3 (es) 2024-09-30
MX2025010400A (es) 2025-10-01
MX2021000516A (es) 2021-04-12
BR112021001655A2 (pt) 2021-05-04
KR20210038697A (ko) 2021-04-07
AU2024205486A1 (en) 2024-08-22
KR20210037743A (ko) 2021-04-06
KR20200033225A (ko) 2020-03-27
KR20240115904A (ko) 2024-07-26
JP6672516B2 (ja) 2020-03-25
RS65630B1 (sr) 2024-07-31
DE112019003835T5 (de) 2021-05-27
TW202024128A (zh) 2020-07-01
PL3829628T3 (pl) 2024-08-19
HRP20240823T1 (hr) 2024-09-27
TWI701041B (zh) 2020-08-11
AU2019315213B2 (en) 2024-05-02
TW202019467A (zh) 2020-06-01
MY210523A (en) 2025-09-29
HUE067057T2 (hu) 2024-09-28
EP3829628B1 (en) 2024-05-15
EP4445913A3 (en) 2025-01-01
JP2020019769A (ja) 2020-02-06
EP4445913A2 (en) 2024-10-16
JP6672533B1 (ja) 2020-03-25
IL280475A (en) 2021-03-01
PH12021550226A1 (en) 2021-10-11
CN112512563A (zh) 2021-03-16
EP3829628C0 (en) 2024-05-15
IL280475B1 (en) 2025-12-01
JP2025065367A (ja) 2025-04-17
TWI704157B (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
KR102365871B1 (ko) C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
JP6672533B1 (ja) Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
RU2832946C2 (ru) Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с c5 заболевания, и способ лечения или предупреждения связанного с c5 заболевания
RU2789389C2 (ru) Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с с5 заболевания, и способ лечения или предупреждения связанного с с5 заболевания

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200312

Application number text: 1020197036896

Filing date: 20191213

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200312

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20200312

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200723

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201127

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200723

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201127

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200903

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200312

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210127

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201223

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20201127

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200903

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200723

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200312

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210329

Application number text: 1020197036896

Filing date: 20191213

PJ0201 Trial against decision of rejection

Patent event date: 20210329

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20210127

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20201127

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2021101000799

Request date: 20210329

J301 Trial decision

Free format text: TRIAL NUMBER: 2021101000799; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20210329

Effective date: 20210531

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20210531

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20210329

Decision date: 20210531

Appeal identifier: 2021101000799